spacer

NDORMS Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences

spacer

Peter Taylor

Publications

Professor Peter C. Taylor

MA, BM, BCh, PhD FRCP

Norman Collisson Professor of Musculoskeletal Sciences

Email: peter.taylor@kennedy.ox.ac.uk

Research Group: Clinical Trials and Translational Research

Peter C. Taylor was appointed to the Norman Collison chair of musculoskeletal sciences at the University of Oxford in October 2011 and is a Fellow of St. Peter’s College, Oxford. He is the Director of Clinical Sciences at the Botnar Research Centre where he directs the NIHR Oxford Musculoskeletal Biomedical Research Unit inflammation theme and leads the rheumatology clinical trials group and related translational research programme at the Kennedy Institute of Rheumatology within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. He was formerly Professor of Experimental Rheumatology at the Kennedy Institute of Rheumatology Division, Imperial College, London, and honorary consultant rheumatologist working in Imperial College NHS Healthcare Trust. He was also Dean of the Charing Cross campus. He studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge and his first degree was in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for studies on pathogenesis of arthritis.

Professor Taylor has specialist clinical interests in rheumatoid arthritis and early inflammatory arthritis. He has over 18 years’ experience in clinical trial design and international leadership in studies of biologic and small molecular therapies in RA and AS. His research interests are in the use of novel imaging for evaluation of prognosis, the assessment of responses to therapy and as an early indicator of inflammation suppression as well as disease modification particularly as applied to early phase clinical trial design. He has recently pioneered studies using such measures as primary outcome measures in early phase Ib/IIa studies with a view to informing later phase study design. He has been a principal investigator in numerous international clinical trials of biologic therapies including the earliest seminal trails of anti-TNF and anti-IL-6 receptor therapy and is currently chief investigator in a number of small molecule therapies in clinical trials for rheumatoid arthritis and ankylosing spondylitis.

Publications

View all publications (the list below shows the past five years). Arranged by year. Sorted by date of publication. Sort by title? Where possible, links point to PubMed. Click icon to switch to Europe PubMed Central spacer

2015

  1. Keystone EC, Taylor PC, Drescher E, Schlichting DE, Beattie SD, Berclaz PY et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Annals of the rheumatic diseases. 2015 Feb; 2(74): 333-340. doi: 10.1136/annrheumdis-2014-206478
  2. Nanus DE, Filer AD, Hughes B, Fisher BA, Taylor PC, Stewart PM et al. TNFα regulates cortisol metabolism in vivo in patients with inflammatory arthritis. Annals of the rheumatic diseases. 2015 Feb; 2(74): 464-469. doi: 10.1136/annrheumdis-2013-203926
  3. Taylor PC, Williams RO. Editorial: combination cytokine blockade: the way forward in therapy for rheumatoid arthritis?. Arthritis & rheumatology (Hoboken, N.J.). 2015 Jan; 1(67): 14-16. doi: 10.1002/art.38893

2014

  1. Taylor PC, Genovese MC, Greenwood M, Ho M, Nasonov E, Oemar B et al. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy. Annals of the rheumatic diseases. 2014 Jul
  2. Gwyer Findlay E, Danks L, Madden J, Cavanagh MM, McNamee K, McCann F et al. OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2014 Feb; 6(111): 2289-2294. doi: 10.1073/pnas.1321071111
  3. Grøn KL, Ornbjerg LM, Hetland ML, Aslam F, Khan NA, Jacobs JW et al. The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program. Clinical and experimental rheumatology. 2014; 6(32): 869-877
  4. Christensen AW, Rifbjerg-Madsen S, Christensen R, Amris K, Taylor PC, Locht H et al. Temporal summation of pain and ultrasound Doppler activity as predictors of treatment response in patients with rheumatoid arthritis: protocol for the FRAME-cohort study. BMJ open. 2014; 1(4): e004313. doi: 10.1136/bmjopen-2013-004313

2013

  1. Kelly S, Humby F, Filer A, Ng N, Di Cicco M, Hands RE et al. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. Annals of the rheumatic diseases. 2013 Dec. doi: 10.1136/annrheumdis-2013-204603
  2. Rastogi A, Taylor PC, Kubassova O, Krasnosselskaia LV, Hajnal JV, Lim AKP et al. Evaluating automated dynamic contrast enhanced wrist 3 T MRI in healthy volunteers: One-year longitudinal observational study. European Journal of Radiology. 2013 Aug; 8(82): 1286-1291. doi: 10.1016/j.ejrad.2013.02.041
  3. Newbould RD, Brown AP, Miller SR, Rao AW, Upadhyay N, Swann P et al. T1-Weighted Sodium MRI of the Articulator Cartilage in Osteoarthritis: A Cross Sectional and Longitudinal Study. PLoS ONE. 2013 Aug; 8(8). doi: 10.1371/journal.pone.0073067
  4. Kapoor SR, Buckley CD, Raza K, Filer A, Fitzpatrick MA, Young SP et al. Metabolic profiling predicts response to anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis. Arthritis and Rheumatism. 2013 Jun; 6(65): 1448-1456. doi: 10.1002/art.37921
  5. Centola M, Turner M, Sutton C, Smith DR, Cavet G, Ramanujan S et al. Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. PLoS ONE. 2013 Apr; 4(8). doi: 10.1371/journal.pone.0060635

2012

  1. Iqbal I, Dasgupta B, Taylor P, Heron L, Pilling C. Elicitation of health state utilities associated with differing durations of morning stiffness in rheumatoid arthritis. Journal of Medical Economics. 2012 Dec; 6(15): 1192-1200. doi: 10.3111/13696998.2012.712927
  2. Khan NA, Spencer HJ, Abda EA, Alten R, Pohl C, Ancuta C et al. Patient's global assessment of disease activity and patient's assessment of general health for rheumatoid arthritis activity assessment: Are they equivalent?. Annals of the Rheumatic Diseases. 2012 Dec; 12(71): 1942-1949. doi: 10.1136/annrheumdis-2011-201142
  3. Page TH, Charles PJ, Piccinini AM, Nicolaidou V, Taylor PC, Midwood KS. Raised circulating tenascin-C in rheumatoid arthritis. Arthritis Research and Therapy. 2012 Nov; 6(14). doi: 10.1186/ar4105
  4. Alzabin S, Palfreeman A, Hull D, McNamee K, Pathan E, Taylor PC et al. Incomplete response of infl ammatory arthritis to blockade is associated with the Th17 pathway. Annals of the Rheumatic Diseases. 2012 Oct; 10(71): 1741-1748. doi: 10.1136/annrheumdis-2011-201024
  5. Choy E, Taylor P, McAuliffe S, Roberts K, Sargeant I. Variation in the use of biologics in the management of rheumatoid arthritis across the UK. Current Medical Research and Opinion. 2012 Oct; 10(28): 1733-1741. doi: 10.1185/03007995.2012.731388
  6. Puntmann VO, D'cruz D, Taylor PC, Hussain T, Indermuhle A, Butzbach B et al. Contrast enhancement imaging in coronary arteries in SLE. JACC: Cardiovascular Imaging. 2012 Sep; 9(5): 962-964. doi: 10.1016/j.jcmg.2012.03.017
  7. Pathan E, Charles PJ, Paterson E, Chowdhury M, Abraham S, Van Rossen E et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Annals of the Rheumatic Diseases. 2012 Sep. doi: 10.1136/annrheumdis-2012-201915
  8. Seymour MW, Kelly S, Beals CR, Malice MP, Bolognese JA, Dardzinski BJ et al. Ultrasound Of Metacarpophalangeal Joints Is A Sensitive And Reliable Endpoint For Drug Therapies In Rheumatoid Arthritis: Results Of A Randomized, Two-Center Placebo-Controlled Study. Arthritis Res Ther. 2012 Sep; 5(14): R198. doi: 10.1186/ar4034
  9. Newbould RD, Miller SR, Toms LD, Swann P, Tielbeek JA, Gold GE et al. T2* Measurement Of The Knee Articular Cartilage In Osteoarthritis At 3T. J Magn Reson Imaging. 2012 Jun; 6(35): 1422-1429. doi: 10.1002/jmri.23598
  10. Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, Jawad A et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway. Ann Rheum Dis. 01 May 2012
  11. Guyot P, Taylor PC, Christensen R, Pericleous L, Drost P, Eijgelshoven I et al. Indirect Treatment Comparison Of Abatacept With Methotrexate Versus Other Biologic Agents For Active Rheumatoid Arthritis Despite Methotrexate Therapy In The United Kingdom. J Rheumatol. 2012 Apr. doi: 10.3899/jrheum.111345
  12. Dignan FL, Scarisbrick JJ, Cornish J, Clark A, Amrolia P, Jackson G et al. Organ-Specific Management And Supportive Care In Chronic Graft-Versus-Host Disease. Br J Haematol. 2012 Apr. doi: 10.1111/j.1365-2141.2012.09131.x
  13. Seymour M, Pétavy F, Chiesa F, Perry H, Lukey PT, Binks M et al. Ultrasonographic Measures Of Synovitis In An Early Phase Clinical Trial: A Double-Blind, Randomised, Placebo And Comparator Controlled Phase Iia Trial Of Gw274150 (A Selective Inducible Nitric Oxide Synthase Inhibitor) In Rheumatoid Arthritis. Clin Exp Rheumatol. 2012 Mar; 2(30): 254-261

2011

  1. Whittle R, Taylor PC. Circulating B-Cell Activating Factor Level Predicts Clinical Response Of Chronic Graft-Versus-Host Disease To Extracorporeal Photopheresis. Blood. 2011 Dec; 24(118): 6446-6449. doi: 10.1182/blood-2011-05-354019
  2. Taylor PC, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z et al. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. J Rheumatol. 2011 Dec;38(12):2572-80. Epub 2011 Nov 15
  3. Taylor PC, Quattrocchi E, Mallett S, Kurrasch R, Petersen J, Chang DJ. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis. 2011 Dec;70(12):2119-25. Epub 2011 Aug 22
  4. Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R et al. Malignancies Associated With Tumour Necrosis Factor Inhibitors In Registries And Prospective Observational Studies: A Systematic Review And Meta-Analysis. Ann Rheum Dis. 2011 Nov; 11(70): 1895-1904. doi: 10.1136/ard.2010.149419
  5. Lebmeier M, Pericleous L, Taylor PC, Christensen R, Drost P, Bergman G et al. MIXED TREATMENT COMPARISON OF BIOLOGIC AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE RESPONDED INADEQUATELY TO METHOTREXATE THERAPY IN THE UNITED KINGDOM. VALUE IN HEALTH. 2011 Nov; 7(14): A317
  6. Lallemand C, Kavrochorianou N, Blanchard B, Tovey MG, Steenholdt C, Ainsworth MA et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists. Journal of Immunological Methods. 2011 Oct; 1-2(373): 229-239. doi: 10.1016/j.jim.2011.08.022
  7. Newbould RD, Miller SR, Tielbeek JA, Toms LD, Rao AW, Gold GE et al. Reproducibility of sodium MRI measures of articular cartilage of the knee in osteoarthritis. Osteoarthritis Cartilage. 2011 Oct 19. [Epub ahead of print]
  8. Taylor PC. Developing anti-TNF and biologic agents. Rheumatology (Oxford, England). 2011 Aug; 8(50): 1351-1353
  9. Mangat P, Taylor P, Abraham S. Respiratory symptoms in a patient on anti-tumour necrosis factor therapy; beware the negative enzyme linked immuno-spot (ELISpot) in suspected mycobacterial disease. QJM. 2011 Jan;104(1):61-3. Epub 2010 May 26
  10. Guyot P, Taylor P, Christensen R, Pericleous L, Poncet C, Lebmeier M et al. Abatacept With Methotrexate Versus Other Biologic Agents In Treatment Of Patients With Active Rheumatoid Arthritis Despite Methotrexate: A Network Meta-Analysis. Arthritis Res Ther. 2011; 6(13): R204. doi: 10.1186/ar3537
  11. Boesen M, Kubassova O, Cimmino MA, Ostergaard M, Taylor P, Danneskiold-Samsoe B et al. Dynamic Contrast Enhanced MRI Can Monitor the Very Early Inflammatory Treatment Response upon Intra-Articular Steroid Injection in the Knee Joint: A Case Report with Review of the Literature. Arthritis. 2011: 578252. doi: 10.1155/2011/578252
  12. Taylor P, Gartemann J, Hsieh J, Creeden J. A systematic review of serum biomarkers anti-cyclic citrullinated peptide and rheumatoid factor as tests for rheumatoid arthritis. Autoimmune Diseases. 2011; 1(1). doi: 10.4061/2011/815038
  13. Puntmann VO, Taylor PC, Barr A, Chiribiri A, Nagel E. UNRAVELLING THE PHENOTYPE OF CARDIOVASCULAR INFLAMMATION IN PATIENTS WITH RHEUMATOID ARTHRITIS WITH MAGNETIC RESONANCE IMAGING: THERAPEUTIC BENEFITS OF TNF INHIBITION. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2011; 1(29): 194

2010

  1. Larché MJ, Seymour M, Lim A, Eckersley RJ, Pétavy F, Chiesa F et al. Quantitative power Doppler ultrasonography is a sensitive measure of metacarpophalangeal joint synovial vascularity in rheumatoid arthritis and declines significantly following a 2-week course of oral low-dose corticosteroids. J Rheumatol. 2010 Dec;37(12):2493-501
  2. Purcaru O, Taylor PC, Emery P, Palmer S. COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL PLUS METHOTREXATE OR AS MONOTHERAPY FOR THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN THE UNITED KINGDOM. VALUE IN HEALTH. 2010 Nov; 7(13): A310
  3. Lebmeier M, Pericleous L, Guyot P, Baig H, Christensen R, Bergman G et al. INDIRECT TREATMENT COMPARISON TO COMPARE EFFICACY IN HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) SCORE FOR BIOLOGIC AGENTS WITH METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ACTIVE DISEASE DESPITE METHOTREXATE THERAPY. VALUE IN HEALTH. 2010 Nov; 7(13): A316
  4. Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. RHEUMATOLOGY. 2010 Oct;49(10):1900-10
  5. Taylor P, Manger B, Alvaro-Gracia J, Johnstone R, Gomez-Reino J, Eberhardt E et al. Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J INT MED RES. 2010 Jul-Aug 38(4):1213-24
  6. Puntmann VO, Taylor PC, Mayr M. Coupling vascular and myocardial inflammatory injury into a common phenotype of cardiovascular dysfunction: systemic inflammation and aging - a mini-review. GERONTOLOGY. Epub 2010 Jun 11
  7. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. CURR OPIN PHARMACOL. 2010 Jun;10(3):308-15
  8. Taylor PC. The importance of the patients' experience of RA compared with clinical measures of disease activity. CLIN EXP RHEUMATOL. 2010 May-Jun;28(3 Suppl. 59):S28-S31
  9. Taylor PC, Mehta P, Tull T. Aetiopathology of rheumatoid arthritis. Medicine. 2010 Apr; 4(38): 163-166. doi: 10.1016/j.mpmed.2009.12.005
  10. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z et al. Golimumab, a new human anti-tumor necrosis factor ? antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. ARTHRITIS RHEUM-US. 2010 Apr;62(4):917-28
  11. Puntmann VO, Taylor PC, Barr A, Schnackenburg B, Jahnke C, Paetsch I. Towards understanding the phenotypes of myocardial involvement in the presence of self-limiting and sustained systemic inflammation: a magnetic resonance imaging study. RHEUMATOLOGY. 2010 Mar;49(3):528-35
  12. Emery P, Treat TTUKSG, Buch MH, Ostör A, Kirkham B, Taylor P et al. Symmetrical polyarthritis. Time for treatment targets in rheumatoid arthritis. BMJ (Clinical research ed.). 2010. doi: 10.1136/bmj.c4170
Related searches:
taylor clinical research treatment therapy
gipoco.com is neither affiliated with the authors of this page nor responsible for its contents. This is a safe-cache copy of the original web site.